Interim analysis of a phase III clinical trial of HER2-positive gastric adenocarinoma shows pembrolizumab plus trastuzumab and chemotherapy improves response rates compared with trastuzumab and chemotherapy alone.
- Yelena Y. Janjigian
- Akihito Kawazoe
- Hyun Cheol Chung